JP2024120882A5 - - Google Patents

Download PDF

Info

Publication number
JP2024120882A5
JP2024120882A5 JP2024025063A JP2024025063A JP2024120882A5 JP 2024120882 A5 JP2024120882 A5 JP 2024120882A5 JP 2024025063 A JP2024025063 A JP 2024025063A JP 2024025063 A JP2024025063 A JP 2024025063A JP 2024120882 A5 JP2024120882 A5 JP 2024120882A5
Authority
JP
Japan
Prior art keywords
alkyl
group
pharma
acceptable salt
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024025063A
Other languages
English (en)
Japanese (ja)
Other versions
JP7737490B2 (ja
JP2024120882A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2024120882A publication Critical patent/JP2024120882A/ja
Publication of JP2024120882A5 publication Critical patent/JP2024120882A5/ja
Priority to JP2025143871A priority Critical patent/JP2025176085A/ja
Application granted granted Critical
Publication of JP7737490B2 publication Critical patent/JP7737490B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024025063A 2023-02-24 2024-02-22 置換ピラゾロピリミジン化合物及びその医薬用途 Active JP7737490B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025143871A JP2025176085A (ja) 2023-02-24 2025-08-29 置換ピラゾロピリミジン化合物及びその医薬用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023027432 2023-02-24
JP2023027432 2023-02-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025143871A Division JP2025176085A (ja) 2023-02-24 2025-08-29 置換ピラゾロピリミジン化合物及びその医薬用途

Publications (3)

Publication Number Publication Date
JP2024120882A JP2024120882A (ja) 2024-09-05
JP2024120882A5 true JP2024120882A5 (enExample) 2025-05-26
JP7737490B2 JP7737490B2 (ja) 2025-09-10

Family

ID=92501386

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024025063A Active JP7737490B2 (ja) 2023-02-24 2024-02-22 置換ピラゾロピリミジン化合物及びその医薬用途
JP2025143871A Pending JP2025176085A (ja) 2023-02-24 2025-08-29 置換ピラゾロピリミジン化合物及びその医薬用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025143871A Pending JP2025176085A (ja) 2023-02-24 2025-08-29 置換ピラゾロピリミジン化合物及びその医薬用途

Country Status (11)

Country Link
EP (1) EP4671247A1 (enExample)
JP (2) JP7737490B2 (enExample)
KR (1) KR20250151389A (enExample)
CN (1) CN120752239A (enExample)
AR (1) AR131919A1 (enExample)
AU (1) AU2024226032A1 (enExample)
CO (1) CO2025011311A2 (enExample)
IL (1) IL322520A (enExample)
MX (1) MX2025009965A (enExample)
TW (1) TW202448887A (enExample)
WO (1) WO2024177127A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025140708A1 (zh) * 2023-12-31 2025-07-03 杭州百新生物医药科技有限公司 吡唑并嘧啶类化合物及其医药用途
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3064498T3 (pl) * 2013-10-30 2020-03-31 Shanghai Hengrui Pharmaceutical Co. Ltd. Pirazolopirymidon lub pochodne pirolotriazonu, sposób ich otrzymywania i ich zastosowania farmaceutyczne
WO2017205766A1 (en) * 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
ES2930151T3 (es) * 2019-01-14 2022-12-07 Innate Tumor Immunity Inc Moduladores heterocíclicos de NLRP3, para su uso en el tratamiento del cáncer
KR102865929B1 (ko) * 2019-01-14 2025-09-29 인네이트 튜머 이뮤니티, 인코포레이티드 Nlrp3 조정제
WO2021132577A1 (ja) * 2019-12-27 2021-07-01 日本たばこ産業株式会社 アシルスルファミド化合物及びその医薬用途
US20240382488A1 (en) * 2021-03-29 2024-11-21 Halia Therapeutics, Inc. Nek7 inhibitors
JP2024513227A (ja) * 2021-04-05 2024-03-22 ハリア・セラピューティクス・インコーポレイテッド Ｎｅｋ７阻害剤
US20240287079A1 (en) * 2021-08-31 2024-08-29 Japan Tobacco Inc. 6-aminopyrazolopyrimidine compound and pharmaceutical use thereof
WO2024048519A1 (ja) * 2022-08-29 2024-03-07 日本たばこ産業株式会社 ピラゾロピリミジン化合物及びその医薬用途
AU2024255473A1 (en) * 2023-04-14 2025-10-16 Takeda Pharmaceutical Company Limited Pyrazolopyrimidine derivatives as inhibitors of nlrp3

Similar Documents

Publication Publication Date Title
JP2023036007A5 (enExample)
JP2024120882A5 (enExample)
JP7169412B2 (ja) 抗癌活性及び抗増殖活性を呈する２－アミノピリミジン－６－オン及び類似体
JPWO2024177126A5 (enExample)
JP2024032686A5 (enExample)
EP2968287B1 (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
CN111315737B (zh) 经砜吡啶烷基酰胺取代的杂芳基化合物
RU2006112428A (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
JP2020526561A5 (enExample)
RU2013156361A (ru) Новые соединения
RU2011121567A (ru) Изоиндолиновые соединения для применения при лечении рака
RU2012138892A (ru) СОЛИ И ПОЛИМОРФЫ 8-ФТОР-2-{4-[(МЕТИЛАМИНО)МЕТИЛ]ФЕНИЛ}-1,3,4,5,-ТЕТРАГИДРО-6Н-АЗЕПИНО[5,4,3-cd]ИНДОЛ-6-ОНА
RU2006112427A (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
RU2016150486A (ru) Ингибиторы бета-лактамазы
JP2008512380A5 (enExample)
JP2012521994A5 (enExample)
RU2014105624A (ru) Соединения индазола, способ их применения и фармацевтическая композиция
JP2017538689A5 (enExample)
JP2003531103A5 (enExample)
CA2561628A1 (en) Histamine h3 receptor agents, preparation and therapeutic uses
IE903749A1 (en) Pyrimidines
JP2005505618A5 (enExample)
CA2705294A1 (en) Methods of treating arthritis by the administration of substituted benzenesulfonamides
RU2018103172A (ru) Кристаллическая фумаратная соль (s)-[3,4-дифтор-2-(2-фтор-4-йодфениламино)фенил][3-гидрокси-3-(пиперидин-2-ил)азетидин-1-ил]метанона
JP2019529460A5 (enExample)